Vaxcyte's new pneumococcal vaccine may only have phase 1/2 results behind it, but analysts are already predicting it could be a major competitor to rival shots from Pfizer and MSD. Just-reported ...

For the pneumococcal vaccine, Sinergium built cold chambers ... Meanwhile, by using its platform to formulate, fill and package in-licensed products (with or without suppliers’ branding ...

The vaccine showed promising results in clinical trials. Although the prevention of pneumonia caused by specific pneumococcal ...

Sanofi SNY and its partner SK bioscience announced that they have expanded their agreement to develop, license and commercialize next-generation pneumococcal conjugate vaccines (PCVs) for treating ...

Pneumococcal 20-valent conjugate vaccine (diphtheria CRM197 protein); contains a total of 46.2mcg saccharides per 0.5mL; susp for IM inj; contains aluminum. After shipping, Prevnar 20 may arrive ...

Alan Kaplan. “The National Advisory Committee on Immunization recommends that all Canadians 65 and older get vaccinated for pneumococcal disease. Talk to your health-care provider to learn more ...

An all-encompassing guide to understanding vaccines. The Bonus Protections of Routine VaccinesVaccination can bring more than just one unexpected benefit. CDC Recommends People Ages 50 to 64 Get ...

Sanofi is handing SK bioscience 50 million euros ($52 million) as the longtime partners take their next-gen pneumococcal conjugate vaccine program into phase 3. The move follows a phase 2 win last ...

Separately, the analyst flagged Pfizer management’s mention of the fourth generation 25-valent pneumococcal vaccine (PCV), which management affirms continues to progress in Phase 2. Shibutani ...

If you haven’t received the pneumonia (pneumococcal) vaccine, you’re among the majority of Americans. Just one in four (25%) people at high risk of pneumococcal disease, an infection that ...